Form 4: Integrated BioPharma Insider Ownership Transfer

Carl DeSantis estate transfers over 11 million shares of Integrated BioPharma to an entity controlled by Damon DeSantis.

Summary

• The filing reports the transfer of 8,966,547 shares of Common Stock from CD Financial, LLC to CDDS 2.0, LLC.
• An additional 2,235,417 shares were transferred from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC.
• The transactions were executed on April 15, 2026, following the passing of the reporting person, Carl DeSantis.
• CDDS 2.0, LLC is controlled by Damon DeSantis.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event related to estate succession rather than a reflection of company performance or strategic shift.

Positives

• The transfer consolidates ownership under a single entity, CDDS 2.0, LLC, which may simplify future governance or strategic decision-making.

Negatives

• The filing confirms the passing of a significant shareholder, Carl DeSantis, which represents a loss of key historical leadership or influence.

Risks

• Potential for shifts in strategic direction or shareholder activism following the consolidation of voting power under new control.

Future Outlook

No specific forward-looking guidance or operational outlook was provided in this ownership disclosure filing.

Industry Context

StockSavvy.ai notes that this filing is a standard administrative update regarding estate planning and ownership succession, which is common in family-controlled public entities and typically does not signal immediate operational changes.

Comparison to Industry Standards

• The filing follows standard SEC reporting requirements for changes in beneficial ownership following the death of a reporting person.
• Consolidation of shares into a family-controlled LLC is a standard practice for estate management in small-cap companies.

Related Party Transactions

• The transfer involves entities controlled by the DeSantis family, specifically CD Financial, LLC, the Carl DeSantis Revocable Trust, and CDDS 2.0, LLC.

Stakeholder Impact

• Shareholders should note the change in the controlling entity for a significant block of shares, though the ultimate beneficial ownership remains within the DeSantis family.

Next Steps

• Continued monitoring of SEC filings for any further changes in control or board composition.

Key Dates

Keywords

Integrated BioPharma, INBP, Insider Ownership, Form 4, Share Transfer, Corporate Governance